Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot neoadjuvant lapatinib study in locally advanced muscle-invasive bladder carcinoma before cystectomy
2009-012714-49Phase 2Active
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lapatinib in bladder cancer and transitional cell carcinoma of the bladder (TCC), sponsored by Centre Hospitalier Universitaire de Bordeaux. Primary endpoints: Molecular effect of 3 weeks of neoadjuvant lapatinib, Proliferation and apoptotic markers and 1 more. Started Sep 2009; status: active.
02
Drugs
lapatinib
03
Conditions
bladder cancertransitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on 2009-012714-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012714-49.